Recent Quotes
My Watchlist
Indicators
Markets
Stocks
ETFs
Tools
Markets:
Overview
News
Currencies
International
Treasuries

Articles published by KaliVir Immunotherapeutics, Inc.

News headline image
KaliVir Immunotherapeutics Announces Closing of $14 Million Series A Extension Financing
From KaliVir Immunotherapeutics, Inc.
Via Business Wire
News headline image
KaliVir Immunotherapeutics Announces Clinical Trial Collaboration and Supply Agreement with Roche to Evaluate VET3-TGI in Combination with Atezolizumab (Tecentriq®) in Advanced Solid Tumors
From KaliVir Immunotherapeutics, Inc.
Via Business Wire
News headline image
KaliVir Immunotherapeutics Announces Completion of First Intravenous Patient Cohort of STEALTH-001 Study Evaluating VET3-TGI in Patients with Advanced Solid Tumors
From KaliVir Immunotherapeutics, Inc.
Via Business Wire
News headline image
KaliVir Immunotherapeutics Announces Completion of First Cohort of STEALTH-001 Study Evaluating VET3-TGI in Patients with Advanced Solid Tumors
From KaliVir Immunotherapeutics, Inc.
Via Business Wire
News headline image
KaliVir Immunotherapeutics Announces Details of Presentation at 2025 American Association for Cancer Research (AACR) Annual Meeting
From KaliVir Immunotherapeutics, Inc.
Via Business Wire
News headline image
KaliVir Immunotherapeutics Strengthens Innovation Portfolio with Issuance of Three New U.S. Patents Covering Its VET™ Product Candidates
From KaliVir Immunotherapeutics, Inc.
Via Business Wire
News headline image
KaliVir Immunotherapeutics Doses First Patient in Phase 1/1b Trial of VET3-TGI for Incurable, Advanced, Solid Tumors
From KaliVir Immunotherapeutics, Inc.
Via Business Wire
News headline image
KaliVir Immunotherapeutics Appoints Schond Greenway as Chief Financial Officer
From KaliVir Immunotherapeutics, Inc.
Via Business Wire
News headline image
KaliVir Immunotherapeutics Announces FDA Clearance of Investigational New Drug (IND) for Oncolytic Immunotherapy VET3-TGI for Solid Tumors
From KaliVir Immunotherapeutics, Inc.
Via Business Wire
News headline image
KaliVir Immunotherapeutics Appoints James M. Burke, M.D., as Chief Medical Officer
From KaliVir Immunotherapeutics, Inc.
Via Business Wire
News headline image
KaliVir Announces Opening of GMP Cleanroom Facility, Increasing Manufacturing Capacity for Oncolytic Viruses
From KaliVir Immunotherapeutics, Inc.
Via Business Wire
News headline image
KaliVir Immunotherapeutics Announces FDA Clearance of Investigational New Drug (IND) for Systemic Oncolytic Virus ASP1012 for Phase I Clinical Trials for Locally Advanced or Metastatic Solid Tumors
From KaliVir Immunotherapeutics, Inc.
Via Business Wire
Stock Quote API & Stock News API supplied by www.cloudquote.io
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the Privacy Policy and Terms Of Service.
© 2025 FinancialContent. All rights reserved.